Maaike H Oosterveer Selected Research

Glucose-6-Phosphatase (Glucose 6 Phosphatase)

8/2022	High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia.
11/2021	Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
11/2020	Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
1/2020	Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
12/2017	Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
1/2017	Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control.
12/2010	Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maaike H Oosterveer Research Topics

Disease

7	Glycogen Storage Disease (Glycogenosis) 11/2021 - 12/2010
6	Metabolic Diseases (Metabolic Disease) 01/2022 - 06/2012
5	Atherosclerosis 01/2020 - 10/2010
4	Hepatorenal form of glycogen storage disease 08/2022 - 01/2017
4	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 01/2021
3	Liver Diseases (Liver Disease) 11/2021 - 08/2012
3	Non-alcoholic Fatty Liver Disease 11/2020 - 02/2017
3	Type 2 Diabetes Mellitus (MODY) 12/2019 - 10/2010
3	Obesity 07/2015 - 12/2011
2	Liver Cell Adenoma (Hepatocellular Adenoma) 08/2022 - 11/2021
2	Hypertriglyceridemia 11/2021 - 01/2021
2	Dyslipidemias (Dyslipidemia) 01/2021 - 03/2010
2	Osteoporosis 01/2020 - 01/2017
2	Inflammation (Inflammations) 01/2020 - 12/2011
2	Neoplasms (Cancer) 01/2019 - 01/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2015 - 01/2014
2	Insulin Resistance 08/2012 - 09/2008
1	Carcinoma (Carcinomatosis) 11/2021
1	Hemorrhage 11/2021
1	Fatty Liver 01/2021
1	Glycogen Storage Disease IB 01/2021
1	Multiple Acyl Coenzyme A Dehydrogenase Deficiency 01/2021
1	Inborn Errors Metabolism (Inborn Errors of Metabolism) 01/2021
1	Hepatomegaly 11/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Sudden Death 12/2017
1	Adenoma (Adenomas) 01/2017
1	Metabolic Bone Diseases (Osteopenia) 01/2017
1	Liver Neoplasms (Liver Cancer) 01/2016
1	Carcinogenesis 01/2016
1	Hyperinsulinism (Hyperinsulinemia) 01/2014
1	Hyperglycemia 01/2014
1	Disease Progression 01/2013

Drug/Important Bio-Agent (IBA)

8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 10/2010
7	Glucose-6-Phosphatase (Glucose 6 Phosphatase)IBA 08/2022 - 12/2010
4	Triglycerides (Triacylglycerol)IBA 08/2022 - 01/2017
4	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020 - 10/2014
3	CarbohydratesIBA 11/2020 - 09/2008
3	CholesterolIBA 01/2017 - 08/2012
2	IsotopesIBA 01/2022 - 09/2008
2	Hypoglycemic Agents (Hypoglycemics)IBA 11/2021 - 01/2021
2	Carrier Proteins (Binding Protein)IBA 11/2020 - 12/2010
2	LipidsIBA 11/2020 - 12/2011
2	Bile Acids and Salts (Bile Acids)IBA 12/2019 - 08/2012
2	Pharmaceutical PreparationsIBA 01/2013 - 08/2012
2	Liver X ReceptorsIBA 01/2013 - 12/2010
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	CorticosteroneIBA 11/2021
1	Adenosine Diphosphate (ADP)IBA 11/2021
1	Prothrombin (Factor II)IBA 11/2021
1	VLDL LipoproteinsIBA 01/2021
1	Starch (Cornstarch)IBA 01/2021
1	empagliflozinIBA 01/2021
1	Nonesterified Fatty Acids (NEFA)IBA 01/2021
1	3-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA 01/2021
1	KetonesIBA 01/2021
1	GlycogenIBA 11/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	LDL Receptors (LDL Receptor)IBA 01/2020
1	Co-Repressor ProteinsIBA 01/2020
1	Vitamin A (Retinol)FDA LinkGeneric 01/2020
1	LigandsIBA 01/2019
1	FructoseIBA 01/2019
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	Hormones (Hormone)IBA 12/2018
1	GlucocorticoidsIBA 12/2018
1	CORT118335IBA 12/2018
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 12/2018
1	Sucrose (Saccharose)IBA 02/2017
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2017
1	Uric Acid (Urate)IBA 01/2017
1	Glutamic Acid (Glutamate)FDA Link 01/2016
1	Transaminases (Aminotransferases)IBA 01/2016
1	Pyruvic Acid (Pyruvate)IBA 01/2016
1	Glutamine (L-Glutamine)FDA Link 01/2016
1	Oxaloacetic Acid (Oxalacetic Acid)IBA 01/2016
1	Volatile Fatty AcidsIBA 07/2015
1	Dietary Fiber FDA Link 07/2015
1	Lysine (L-Lysine)FDA Link 10/2014
1	Insulin (Novolin)FDA Link 01/2014
1	Fatty Acids (Saturated Fatty Acids)IBA 08/2012
1	NAD (NADH)IBA 06/2012
1	nicotinamide-beta-ribosideIBA 06/2012
1	Sirtuin 1IBA 06/2012
1	EndocannabinoidsIBA 12/2011
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 12/2011
1	6alpha-ethyl-23(S)-methylcholic acidIBA 12/2011
1	Liver GlycogenIBA 12/2010
1	Blood Glucose (Blood Sugar)IBA 03/2010

Therapy/Procedure

2	Glycemic Control 11/2021 - 01/2021
1	Precision Medicine 01/2017
1	Therapeutics 01/2013